RT Journal Article
SR Electronic
T1 Influenza vaccination reveals and partly reverses sex dimorphic immune imprints associated with prior mild COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.17.22271138
DO 10.1101/2022.02.17.22271138
A1 Sparks, Rachel
A1 Lau, William W.
A1 Liu, Can
A1 Han, Kyu Lee
A1 Vrindten, Kiera L.
A1 Sun, Guangping
A1 Cox, Milann
A1 Andrews, Sarah F.
A1 Bansal, Neha
A1 Failla, Laura E.
A1 Manischewitz, Jody
A1 Grubbs, Gabrielle
A1 King, Lisa R.
A1 Koroleva, Galina
A1 Leimenstoll, Stephanie
A1 Snow, LaQuita
A1 ,
A1 Chen, Jinguo
A1 Tang, Juanjie
A1 Mukherjee, Amrita
A1 Sellers, Brian A.
A1 Apps, Richard
A1 McDermott, Adrian B.
A1 Martins, Andrew J.
A1 Bloch, Evan M.
A1 Golding, Hana
A1 Khurana, Surender
A1 Tsang, John S.
YR 2022
UL http://medrxiv.org/content/early/2022/02/22/2022.02.17.22271138.abstract
AB Viral infections can have profound and durable functional impacts on the immune system. There is an urgent need to characterize the long-term immune effects of SARS-CoV-2 infection given the persistence of symptoms in some individuals and the continued threat of novel variants including the recent rapid acceleration in infections. As the majority of COVID-19 patients experienced mild disease, here we use systems immunology approaches to comparatively assess the post-infection immune status (mean: 151 [5th – 95th percentile: 58 – 235] days after diagnosis) and subsequent innate and adaptive responses to seasonal influenza vaccination (as an “immune challenge”) in 33 previously healthy individuals after recovery from mild, non-hospitalized COVID-19, as compared to 40 age- and sex-matched healthy controls with no history of COVID-19. Sex-specific, temporally stable shifts in signatures of metabolism, T-cell activation, and innate immune/inflammatory processes suggest that mild COVID-19 can establish new post-infection immunological set-points. COVID-19-recovered males had an increase in CD71hi B-cells (including influenza-specific subsets) before vaccination and more robust innate, influenza-specific plasmablast, and antibody responses after vaccination compared to healthy males. Intriguingly, by day 1 post-vaccination in COVID-19-recovered subjects, the expression of numerous innate defense/immune receptor genes (e.g., Toll-like receptors) in monocytes increased and moved away from their post-COVID-19 repressed state toward the pre-vaccination baseline of healthy controls, and these changes tended to persist to day 28 in females, hinting that the acute inflammatory responses induced by vaccination could partly reset the immune states established by prior mild COVID-19. Our study reveals sex-dimorphic immune imprints and in vivo functional impacts of mild COVID-19 in humans, suggesting that prior COVID-19 could change future responses to vaccination and in turn, vaccines could help reset the immune system after COVID-19, both in an antigen-agnostic manner.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04025580 Funding StatementThis research was supported by the Intramural Research Programs of the NIAID and the Intramural Programs of the NIH Institutes supporting the NIH Center for Human Immunology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study participants were enrolled on National Institutes of Health (NIH) protocol 19-I-0126 (Systems analyses of the immune response to the seasonal influenza vaccine; NCT04025580), approved by the NIH Institutional Review Board. Informed consent was obtained from all participants and all relevant ethical regulations have been complied.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw and processed data from the whole blood bulk RNAseq are available from the NCBI Gene Expression Omnibus, accession number GEO: GSE194378 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE194378; will be released to public at the time of publication). Additional datasets, including clinical, proteomics, flow cytometry, CITE-seq, and influenza antibody measurements, are available at: https://doi.org/10.5281/zenodo.5935845 (will be released to public at time of publication). The influenza infection dataset we utilized was downloaded directly from GEO: GSE68310 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68310). https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE194378 https://doi.org/10.5281/zenodo.5935845